Manuscripts

Correlation of self‑reported racial background to euploidy status and live birth rates in assisted reproductive technology cycles

Purpose To determine whether the embryonic euploidy rate and live birth outcomes following single, euploid embryo
transfer (SEET) difer among women of self-reported racial and ethnic backgrounds.

Methods This retrospective cohort study included all infertile patients of diferent self-reported racial backgrounds who underwent In vitro fertilization (IVF) with preimplantation genetic testing for aneuploidy (PGT-A) and an autologous single euploid embryo transfer (SEET) from December 2015 to December 2019 at a single private and academic assisted reproduction technology center. Primary outcome measures included ploidy rates among diferent racial groups. Secondary outcomes included clinical pregnancy, clinical pregnancy loss, and live birth rates.

Results Five thousand fve hundred sixty-two patients who underwent an IVF cycle with ICSI-PGT-A were included. A
total of 24,491 blastocysts were analyzed. White participants had on average more euploid embryos and higher euploidy
rates when compared to their counterparts (p≤0.0001). However, after controlling for confounding factors, there was no
association between race and the odds of having a higher euploidy rate (aOR 1.31; 95% CI 0.63–2.17, p=0.42). A total of
4949 patients underwent SEET. Pregnancy outcomes did not difer among patients of varying self-reported races.

Conclusions Euploidy rates and pregnancy outcomes were comparable among patients of diferent racial backgrounds who underwent a SEET.

Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors

Introduction: Fertility-related concerns cause significant anxiety among patients with Hereditary Breast and Ovarian Cancer Syndrome (HBOC). The Society of Gynecologic Oncology and the American Society for Reproductive Medicine recommend patients diagnosed with HBOC receive early referral to a reproductive endocrinologist. However, evidence about fertility trends in this patient population are limited and guidelines are scarce. The aim of this study is to compare fertility preservation among patients with HBOC to control patients undergoing fertility treatment without a diagnosis of infertility.

Methods: This retrospective study included patients who presented to a single academic institution for fertility preservation in the setting of diagnosis of HBOC. In this study, HBOC patients are referred to as those who had tested positive for pathogenic mutations in BRCA1, BRCA2 or were at high-risk for HBOC based on a strong family history (defined as >3 family members diagnosed with HBOC) without a genetic mutation. HBOC patients were matched in a 1:1 fashion to a control group undergoing fertility preservation without a diagnosis of infertility or HBOC. All analysis was done using SPSS version 9.4 (SAS Institute, Cary, NC).

Results: Between August 1st, 2016 and August 1st, 2022, 81 patients presented to the study center for consultation in the setting of HBOC. Of those who presented, 48 (59.2%) ultimately underwent oocyte cryopreservation and 33 (40.7%) underwent embryo cryopreservation. Patients who underwent oocyte cryopreservation due to BRCA1 status were more likely to present for fertility consultation at a younger age compared to control patients (32.6 vs. 34.7 years, p = 0.03) and were more likely to undergo oocyte cryopreservation at a younger age (32.1 vs. 34.6 years, p = 0.007). There was no difference in age at initial consultation or age at procedure for patients with BRCA2 or patients with a strong family history compared to control patients (p > 0.05). There was no difference in the mean age of patients with HBOC at presentation for consultation for embryo cryopreservation or the mean age the patient with HBOC underwent embryo cryopreservation compared to control patients (p > 0.05). Patients with BRCA1 or BRCA2 did not have expedited time from consultation to first cycle start (p > 0.05). After adjusting for factors including anti-Müllerian hormone (AMH) level and age, patients considered in the HBOC group due to family history had less time between consultation and oocyte cryopreservation cycle compared to control patients. (179 vs. 317 days, p = 0.045). There was no difference in time from consultation to starting cycle for embryo cryopreservation for patients with HBOC compared to controls (p > 0.05).

Conclusion: Patients with HBOC did not undergo expedited fertility treatment compared to control patients undergoing oocyte and embryo cryopreservation for non-infertility reasons. Patients diagnosed with BRCA1 had more oocytes retrieved compared to the control population which is possibly due to earlier age of presentation in the setting of recommended age of risk reducing surgery being age 35–40. When age matched, cycle outcomes did not differ between HBOC and control patients. Given the known cancer prevention benefit and recommendations for risk-reducing surgery, future studies should focus on guidelines for fertility preservation for patients with HBOC.

Effect of Postthaw Change in Embryo Score on Single Euploid Embryo Transfer Success Rates

Objective: To assess whether the change in embryo morphology from precryopreservation to postthaw is associated with the embryo transfer success rates in single euploid embryo transfer cycles.

Design: Retrospective cohort study.

Setting: Academic affiliated fertility clinic.

Patient(s): Patients who underwent a single euploid embryo transfer cycle from September 2016 to April 2022 were included. A decision support tool was used to assign each embryo a reproductive potential score on the basis of the day of biopsy, expansion, and grade of trophectoderm and inner cell mass at the time of cryopreservation and after thaw. Embryos were divided into 4 groups: group 1included embryos with the same score after thaw (reference); group 2 included those with a higher score; group 3 included those with a lower score; and group 4 included those that did not re-expand after thaw.

Intervention(s): No interventions administered.

Main Outcome Measure(s): The primary outcome was the live birth rates (LBRs) per embryo transfer. The secondary outcomes included the chemical pregnancy, clinical pregnancy, and clinical pregnancy loss rates. Comparative statistics and univariate analyses were performed using the Kruskal-Wallis and c2 tests. Multivariate logistic regression fitted with generalized estimating equation was performed to compare the odds of live birth between groups.

Result(s): A total of 7,750 embryo transfers performed for 4,613 patients met inclusion criteria: 5,331 in group 1; 486 in group 2; 1,726 in group 3; and 207 in group 4. In the univariate analysis, there was a statistically significant difference in the LBR between groups 1, 2, 3, and 4 (55.8% vs. 51.4%, 47.5%, and 26.6%). Logistic regression controlling for oocyte age, antimullerian hormone, body mass index, € endometrial thickness, year of embryo transfer, time from thaw to final grading, and embryo score before cryopreservation showed significantly lower odds of live birth when the embryo was downgraded (odds ratio [OR], 0.70; confidence interval [CI], 0.62–0.79) or did not re-expand (OR, 0.36; CI, 0.26–0.51) than those with no change in score. When controlling for all variables, there was a significant increase in the odds of live birth between embryos that had a higher score after thaw and those without a change (OR, 1.42; CI, 1.14–1.76). There was no significant difference in the clinical pregnancy loss rate among the 4 groups.

Conclusion(s): The change in the quality of the embryo after thaw is an important factor in embryo transfer success. In an adjusted analysis, the chemical and clinical pregnancy rates and LBR per embryo transfer all significantly decrease in embryos that were downgraded or did not expand on the day of single euploid embryo transfer. Embryos that re-expand and have improved quality after thaw have the highest odds of live birth. (Fertil Steril
2024;-:-–-. 2024 by American Society for Reproductive Medicine.)

Recent clomiphene citrate exposure does not impact subsequent clinical outcomes in single euploid frozen embryo transfer cycles

Carlos Hernandez-Nieto,, Joseph Lee, Tamar Alkon-Meadows, Luz Soto-Cossio, Benjamin Sandler, Tanmoy …

Fertility treatment outcomes in transgender men with a history of testosterone therapy

Atoosa Ghofranian, M.D.,Samantha L. Estevez, M.D.,Caroline Gellman, M.D., Dmitry Gounko, B.S., …

Evaluating in vitro fertilization outcomes of patients with low body mass index following frozen-thawed embryo transfer

Oliva M, Nazem TG, Lee JA, Copperman AB. Int J Gynaecol Obstet. 2021 Oct;155(1):132-137. Epub 2021 …

Understanding the Reproductive Experience and Pregnancy Outcomes of Lesbian Women Undergoing Donor Intrauterine Insemination

Nazem TG, Chang S, Lee JA, Briton-Jones C, Copperman AB, McAvey B. LGBT Health. 2019 …

Paternal contribution to embryonic competence

Stein D, Ukogu C, Ganza A, Gounko D, Lee J, Bar-Chama N, Copperman AB. Cent European J Urol. …

What is the reproductive potential of day 7 euploid embryos?

Hernandez-Nieto, C., Lee, J. A., Slifkin, R., Sandler, B., Copperman, A. B., & Flisser, E. …

How time to healthy singleton delivery could affect decision-making during infertility treatment: a Delphi consensus

Bosch, E., Bulletti, C., Copperman, A. B., Fanchin, R., Yarali, H., Petta, C. A., Polyzos, N. P., …

Identifying at-risk populations: are we simply not doing enough fertility preservation procedures?

Flisser E. (2018). Fertility and Sterility, 110(4), 640–641. June 18, 2018. Download

Co-ivf for same-sex female couples

Chloe Getrajdman, BA; Joseph A. Lee, BA; Alan B. Copperman, MD. Semin Reprod Med 2017;00:1–5. …

Beauty, brains or health: trends in ovum recipient preferences

Flores H, Lee J, Rodriguez-Purata J, Witkin G, Sandler B, Copperman AB. Womens Health (Larchmt). …

Medical versus surgical treatment for early pregnancy loss in infertile patients - Which approach facilitates more rapid return to subsequent treatment cycle?

Victoria Vallejo, Hilde I.G. Cotton, Joseph A. Lee, Enrique Cervantes, Benjamin Sandler M.D, Alan B …